IGM Biosciences
IGMS
IGMS was delisted on the 13th of August, 2025.
72 hedge funds and large institutions have $357M invested in IGM Biosciences in 2024 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 25 increasing their positions, 24 reducing their positions, and 19 closing their positions.
133% more capital invested
Capital invested by funds: $153M → $357M (+$204M)
39% more call options, than puts
Call options by funds: $1.2M | Put options by funds: $863K
4% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 24
2.66% less ownership
Funds ownership: 66.18% → 63.52% (-2.7%)
12% less funds holding
Funds holding: 82 → 72 (-10)
47% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$2.44M |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$624K |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$322K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$308K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$216K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$22.9M |
| 2 |
Millennium Management
New York
|
-$2.84M |
| 3 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$1.06M |
| 4 |
Goldman Sachs
New York
|
-$818K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$737K |
IGMS Hedge Fund Activity: Q3 2024 in Review
72 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in IGM Biosciences (IGMS) for Q3 2024, worth a combined $357M — up 133% from $153M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of IGMS and 10 opened new positions — a net loss of 9 holders — while 24 trimmed existing stakes and 25 added.
The largest buyer was Invesco, opening a new position worth an estimated $2.44M. The largest seller was Artal Group, exiting entirely with an estimated $22.9M sold.
- 72 institutional investors held IGM Biosciences (IGMS) as of Q3 2024, down from 82 in Q2 2024.
- Funds reported $357M of IGM Biosciences stock for Q3 2024, up 133% quarter-over-quarter.
- 10 funds opened new IGM Biosciences positions in Q3 2024 and 19 closed out, a net change of -9 holders.
- The largest IGM Biosciences buyer in Q3 2024 was Invesco, an estimated $2.44M added.
- The largest IGM Biosciences seller in Q3 2024 was Artal Group, an estimated $22.9M sold.
Based on aggregated 13F filings for Q3 2024.